Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7245208 | 0.93 | POLB (0.39) | L3MBTL1KDM4EHRH3KMT2AMEN1 | |
| SCHEMBL6152414 | 0.89 | PTAFR (0.37) | HPGDL3MBTL1KDM4EHRH3HTR4 | |
| SCHEMBL6153190 | 0.87 | SMN1; SMN2 (0.37) | HRH3KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL6152961 | 0.83 | HTR1A (0.30) | — | |
| SCHEMBL6153216 | 0.83 | CCR3 (0.32) | KDM4EKMT2AMEN1ALDH1A1 | |
| SCHEMBL6152882 | 0.82 | POLB (0.39) | L3MBTL1KDM4EHRH3KMT2AMEN1 | |
| SCHEMBL6153461 | 0.82 | CYP4F2 (0.34) | HPGDKDM4EKMT2AMEN1ALDH1A1 | |
| SCHEMBL6153189 | 0.81 | CYP2C9 (0.32) | HPGDL3MBTL1KDM4EKMT2AMEN1 | |
| Succinic Acid SCHEMBL6152801 | 0.81 | CCR3 (0.31) | KDM4EALDH1A1 | |
| SCHEMBL7245220 | 0.81 | TBXA2R (0.47) | HPGDKDM4EROCK1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307449-B1 | 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS | PFIZER PHARMA (JP) | 2005-12-07 | — | — | EP | disclosed |
| US-6653313-B2 | For treatment and prevention of inflammation, asthma, allergic rhinitis, pain and other disorders | WARNER-LAMBERT COMPANY LLC | 2003-11-25 | — | — | US | disclosed |
| US-20020161006-A1 | 1,4-dihydropyridine compounds as bradykinin antagonists | KAWAMURA MITSUHIRO (US) | 2002-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161006-A1 | 1,4-dihydropyridine compounds as bradykinin antagonists | BDKRB1, BDKRB2, HRH4 | HPGD 511/4885L3MBTL1 3714/4885KDM4E 1330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.